医药生物 G [Table_ReportDate] 2025 年 08 月 25 日 [Table_Author] 分析师：王俐媛 执业证书号：S1030524080001 电话：0755-83199599 邮箱：wangly1@csco.com.cn 研究助理：徐伊琳 电话：0755-23602217 邮箱：xuyl@csco.com.cn 公司具备证券投资咨询业务资格 证券研究报告 MRD 有望成为新的免疫伴随诊断 [Table_ReportType] 医药生物行业周报（8 月第 4 周） [Table_S 行业ummary 观点：] 请务必阅读文后重要声明及免责条款 [Table_Industry] [Table_BaseData] 1) 周度回顾。上周（8 月 18 日-8 月 22 日）医药生物板 块收涨 1.05%，跑输 Wind 全 A（3.87%）和沪深 300 （4.18%）。从板块来看，医疗设备（4.49%）、疫苗 （4.41%）和中药（2.86%）涨幅居前，医疗研发外包 （-3%）、原料药（-1.44%）和医疗耗材（-0.01%）跌幅 居前。从个股来看，香雪制药（40.4%）、欧林生物 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 66.40 [9][14]. Core Insights - The ADC (Antibody-Drug Conjugates) sector is experiencing significant growth, with the company reporting a 71% year-over-year increase in order reserves, totaling USD 991 million by the end of 2024 [5][4]. - The company is advancing its global dual-plant strategy, with production facilities in both domestic and overseas locations being developed in an orderly manner [3][6]. - The company is expected to achieve a compound annual growth rate (CAGR) of 36% from 2024 to 2026, with adjusted net profits projected at RMB 1.62 billion, RMB 2.17 billion, and RMB 2.58 billion for 2025, 2026, and 2027 respectively [7][14]. Summary by Sections ADC Industry Development - The ADC industry is witnessing a surge in commercialization and late-stage clinical production demand, driven by recent FDA approvals of new ADCs and increased global clinical registrations by multinational corporations [4]. - Domestic ADC molecules are leading a new wave of innovation, with significant participation in major conferences and substantial business development activities [4]. Order and Growth Momentum - The company has a robust order backlog, with a total of 194 projects (up 36% year-over-year) and 15 Phase III clinical projects as of the end of 2024 [5]. - The completion of the Singapore facility is expected to attract more overseas project orders [5]. Global Dual-Plant Strategy - The new production facility in XBCM2 L2 is set to produce 60 batches of 2,000L scale antibody intermediates and 80 batches of 1,000L scale conjugated solutions annually, enhancing commercial production capacity [6]. - Expansion plans in Wuxi and the successful construction of the Singapore facility are anticipated to begin receiving overseas orders by the end of 2025 [6]. Profit Forecast and Valuation - The company’s revenue is projected to reach RMB 58.3 billion, RMB 76.1 billion, and RMB 94.1 billion for 2025, 2026, and 2027 respectively, with adjusted net profits of RMB 16.2 billion, RMB 21.7 billion, and RMB 25.8 billion [14][18]. - The report maintains a price-to-earnings (PE) ratio of 45.92 for 2025, reflecting the strong demand in the ADC sector and the company's capacity expansion [7][14].